Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
Myriad: Q4 Earnings Snapshot
Myriad: Q4 Earnings Snapshot
Associated Press Finance
Tue, February 24, 2026 at 6:52 AM GMT+9 1 min read
In this article:
MYGN
+2.10%
SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Myriad Genetics Inc. (MYGN) on Monday reported a loss of $7.9 million in its fourth quarter.
The Salt Lake City-based company said it had a loss of 8 cents per share. Earnings, adjusted for costs related to mergers and acquisitions and asset impairment costs, came to 4 cents per share.
The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 2 cents per share.
The molecular diagnostic company posted revenue of $209.8 million in the period.
For the year, the company reported a loss of $365.9 million, or $3.95 per share. Revenue was reported as $824.5 million.
Myriad expects full-year revenue in the range of $860 million to $880 million.
This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on MYGN at
Terms and Privacy Policy
Privacy Dashboard
More Info